Oncogenic growth factor signaling mediating tumor escape from cellular immunity

Current Opinion in Immunology

Volumn 45, Issue , 2017, Pages 52-59

  Concha Benavente, Fernando ^a,b   Ferris, Robert L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA ANTIGEN CLASS 1; PROGRAMMED DEATH 1 LIGAND 1; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PATHOLOGY; PROTO ONCOGENE; T LYMPHOCYTE;

ANIMALS; GENES, ERBB; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 85012180618     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2017.01.004     Document Type: Review

References (59)

1. 1 Linggi, B., Carpenter, G., ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 16 (2006), 649–656.
2. 2 Marmor, M.D., Skaria, K.B., Yarden, Y., Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58 (2004), 903–913.
3. 3 Warren, C.M., Landgraf, R., Signaling through ERBB receptors: multiple layers of diversity and control. Cell Signal 18 (2006), 923–933.
4. 4 Hanahan, D., Weinberg, R.A., The hallmarks of cancer. Cell 100 (2000), 57–70.
5. 5 Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
6. 6 Harari, D., Yarden, Y., Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19 (2000), 6102–6114.
7. 7 Blume-Jensen, P., Hunter, T., Oncogenic kinase signalling. Nature 411 (2001), 355–365.
8. 8 Wada, T., Qian, X.L., Greene, M.I., Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61 (1990), 1339–1347.
9. 9 Gan, H.K., Cvrljevic, A.N., Johns, T.G., The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J 280 (2013), 5350–5370.
10. 10 Ohashi, K., Maruvka, Y.E., Michor, F., Pao, W., Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 31 (2013), 1070–1080.
11. 11 Wieduwilt, M.J., Moasser, M.M., The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 65 (2008), 1566–1584.
12. 12 Stamos, J., Sliwkowski, M.X., Eigenbrot, C., Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277 (2002), 46265–46272.
13. 13 Yun, C.H., Boggon, T.J., Li, Y., Woo, M.S., Greulich, H., Meyerson, M., Eck, M.J., Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11 (2007), 217–227.
14. 14 Srivastava, R.M., Lee, S.C., Andrade Filho, P.A., Lord, C.A., Jie, H.B., Davidson, H.C., Lopez-Albaitero, A., Gibson, S.P., Gooding, W.E., Ferrone, S., et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 19 (2013), 1858–1872.
15. 15 Meissner, M., Reichert, T.E., Kunkel, M., Gooding, W., Whiteside, T.L., Ferrone, S., Seliger, B., Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11 (2005), 2552–2560.
16. 16 Lopez-Albaitero, A., Nayak, J.V., Ogino, T., Machandia, A., Gooding, W., DeLeo, A.B., Ferrone, S., Ferris, R.L., Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 176 (2006), 3402–3409.
17. 17 Leibowitz, M.S., Srivastava, R.M., Andrade Filho, P.A., Egloff, A.M., Wang, L., Seethala, R.R., Ferrone, S., Ferris, R.L., SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clin Cancer Res 19 (2013), 798–808.
18. 18 Seliger, B., Kiessling, R., The two sides of HER2/neu: immune escape versus surveillance. Trends Mol Med 19 (2013), 677–684.
19. 19 Agazie, Y.M., Hayman, M.J., Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol Cell Biol 23 (2003), 7875–7886.
20. 20 Sapkota, B., Hill, C.E., Pollack, B.P., Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells. Oncoimmunology, 2, 2013, e22890.
21. 21 Concha-Benavente, F., Srivastava, R.M., Ferrone, S., Ferris, R.L., EGFR-mediated tumor immunoescape: the imbalance between phosphorylated STAT1 and phosphorylated STAT3. Oncoimmunology, 2, 2013, e27215.
22. 22• Srivastava, R.M., Trivedi, S., Concha-Benavente, F., Hyun-Bae, J., Wang, L., Seethala, R.R., Branstetter, BFT, Ferrone, S., Ferris, R.L., STAT1-induced HLA class I upregulation enhances immunogenicity and clinical response to anti-EGFR mAb cetuximab therapy in HNC patients. Cancer Immunol Res 3 (2015), 936–945 Authors demostrate that EGFR induces HLA class I downregulation via SHP2-STAT1 suppression, EGFR blockade with cetuximab induced upregulation of IFNγ receptor, STAT1 activation and upregulation of HLA-B/C alleles more than HLA-A alleles. HLA class I upregulation was significantly associated with clincal response to cetuximab in a single agent neo-adjuvant phase II clinical trial.
23. 23 Seliger, B., Maeurer, M.J., Ferrone, S., Antigen-processing machinery breakdown and tumor growth. Immunol Today 21 (2000), 455–464.
24. 24 Chang, C.C., Ogino, T., Mullins, D.W., Oliver, J.L., Yamshchikov, G.V., Bandoh, N., Slingluff, C.L. Jr., Ferrone, S., Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem 281 (2006), 18763–18773.
25. 25 Herrmann, F., Lehr, H.A., Drexler, I., Sutter, G., Hengstler, J., Wollscheid, U., Seliger, B., HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 64 (2004), 215–220.
26. 26 Zaks, T.Z., Rosenberg, S.A., Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 58 (1998), 4902–4908.
27. 27 Choudhury, A., Charo, J., Parapuram, S.K., Hunt, R.C., Hunt, D.M., Seliger, B., Kiessling, R., Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 108 (2004), 71–77.
28. 28 Mimura, K., Ando, T., Poschke, I., Mougiakakos, D., Johansson, C.C., Ichikawa, J., Okita, R., Nishimura, M.I., Handke, D., Krug, N., et al. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer 128 (2011), 390–401.
29. 29 Bukur, J., Herrmann, F., Handke, D., Recktenwald, C., Seliger, B., Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J Biol Chem 285 (2010), 30419–30426.
30. 30 Inoue, M., Mimura, K., Izawa, S., Shiraishi, K., Inoue, A., Shiba, S., Watanabe, M., Maruyama, T., Kawaguchi, Y., Inoue, S., et al. Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology 1 (2012), 1104–1110.
31. 31 Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., Roche, P.C., Lu, J., Zhu, G., Tamada, K., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8 (2002), 793–800.
32. 32 Tseng, S.Y., Otsuji, M., Gorski, K., Huang, X., Slansky, J.E., Pai, S.I., Shalabi, A., Shin, T., Pardoll, D.M., Tsuchiya, H., B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 193 (2001), 839–846.
33. 33 Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
34. 34 Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
35. 35 Ferris, R.L., Blumenschein, G. Jr., Fayette, J., Guigay, J., Colevas, A.D., Licitra, L., Harrington, K., Kasper, S., Vokes, E.E., Even, C., et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375 (2016), 1856–1867.
36. 36 Kimura, Y., Oki, E., Yoshida, A., Aishima, S., Zaitsu, Y., Ohtsu, H., Ando, K., Ida, S., Saeki, H., Morita, M., et al. Significance of accurate human epidermal growth factor receptor-2 (HER2) evaluation as a new biomarker in gastric cancer. Anticancer Res 34 (2014), 4207–4212.
37. 37 Akbay, E.A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J.H., Christensen, C.L., Mikse, O.R., Cherniack, A.D., Beauchamp, E.M., Pugh, T.J., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 3 (2013), 1355–1363.
38. 38• Concha-Benavente, F., Srivastava, R.M., Trivedi, S., Lei, Y., Chandran, U., Seethala, R.R., Freeman, G.J., Ferris, R.L., et al. Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNgamma that induce PD-L1 expression in head and neck cancer. Cancer Res 76 (2016), 1031–1043 Authors identify tumor cell extrinsic (IFNγ mediated) and intrinsic (EGFR mediated) pathways that induce PD-L1 expression. Importantly, these pathways use JAK2/STAT1 as a common signaling pathway for PD-L1 upregulation. This is the first study that reports the signaling pathway that induces PD-L1 expression downstream wild type EGFR. These findings are clinically relevant since EGFR expression in large cohort of head and neck quamous cell carcinoma specimens (TCGA,n = 500) significantly correlated with JAK2 and PD-L1 expression. Specific JAK2 inhibition prevented IFNγ and EGFR induced PD-L1 upregulation.
39. 39 Stransky, N., Egloff, A.M., Tward, A.D., Kostic, A.D., Cibulskis, K., Sivachenko, A., Kryukov, G.V., Lawrence, M.S., Sougnez, C., McKenna, A., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333 (2011), 1157–1160.
40. 40 McBride, S.M., Rothenberg, S.M., Faquin, W.C., Chan, A.W., Clark, J.R., Ellisen, L.W., Wirth, L.J., Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma. Head Neck 36 (2014), 1181–1188.
41. 41•• The Cancer Genome Atlas Network, Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517 (2015), 576–582 Characterization of 279 head and neck squamous cell carcinoma specimens identified important mutations in different subsets of patients. HPV-positive patients had PIK3CA, TRAF3 loss-of-function mutations. Smokers had TP53, CDKN2A inactivating mutations. Patients with favourable clinical outcomes had activating mutations of HRAS or PIK3CA coupled with inactivating mutations in CASP8, NOTCH1 and TP53. Importantly, this study identifies altered pathways that are elegible for therapeutic targets.
42. 42•• Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D.Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375 (2016), 819–829 Authors describe critical loss-of-function mutations in the IFNγ receptor pathway that are associated to resistance to anti-PD-1 therapy in melanoma patients. JAK1, JAK2 and B2M inactivating mutations were reported in specimens from patients who relapsed after anti-PD1 therapy with pembrolizumab.
43. 43 Lyford-Pike, S., Peng, S., Young, G.D., Taube, J.M., Westra, W.H., Akpeng, B., Bruno, T.C., Richmon, J.D., Wang, H., Bishop, J.A., et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 73 (2013), 1733–1741.
44. 44• Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461 Comprehensive review of different checkpoint receptors and ligands expressed in the tumor microenvironment, drugs that have been FDA approved targeting CTLA-4, PD-1, PD-L1, mechanism of tumor resistance to innate and adaptive immunity and candidate combination therapies are discussed.
45. 45 Marzec, M., Zhang, Q., Goradia, A., Raghunath, P.N., Liu, X., Paessler, M., Wang, H.Y., Wysocka, M., Cheng, M., Ruggeri, B.A., et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 105 (2008), 20852–20857.
46. 46 Parsa, A.T., Waldron, J.S., Panner, A., Crane, C.A., Parney, I.F., Barry, J.J., Cachola, K.E., Murray, J.C., Tihan, T., Jensen, M.C., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13 (2007), 84–88.
47. 47 Mescher, M.F., Curtsinger, J.M., Agarwal, P., Casey, K.A., Gerner, M., Hammerbeck, C.D., Popescu, F., Xiao, Z., Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 211 (2006), 81–92.
48. 48 Burkholder, B., Huang, R.Y., Burgess, R., Luo, S., Jones, V.S., Zhang, W., Lv, Z.Q., Gao, C.Y., Wang, B.L., Zhang, Y.M., et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 1845 (2014), 182–201.
49. 49 Rabinovich, G.A., Gabrilovich, D., Sotomayor, E.M., Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25 (2007), 267–296.
50. 50 Fletcher, E.V., Love-Homan, L., Sobhakumari, A., Feddersen, C.R., Koch, A.T., Goel, A., Simons, A.L., EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC. Mol Cancer Res 11 (2013), 1574–1584.
51. 51 Gelfo, V., Rodia, M.T., Pucci, M., Dall'Ora, M., Santi, S., Solmi, R., Roth, L., Lindzen, M., Bonafe, M., Bertotti, A., et al. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors. Oncotarget 7 (2016), 72167–72183.
52. 52 Vazquez-Martin, A., Colomer, R., Menendez, J.A., Her-2/neu-induced cytokine signature in breast cancer. Adv Exp Med Biol 617 (2008), 311–319.
53. 53 Dehqanzada, Z.A., Storrer, C.E., Hueman, M.T., Foley, R.J., Harris, K.A., Jama, Y.H., Shriver, C.D., Ponniah, S., Peoples, G.E., Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol Rep 17 (2007), 687–694.
54. 54 Allen, C.T., Clavijo, P.E., Van Waes, C., Chen, Z., Anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches. Cancers (Basel) 7 (2015), 2397–2414.
55. 55 Li, J., Srivastava, R.M., Ettyreddy, A., Ferris, R.L., Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. J Immunother Cancer, 3, 2015, 54.
56. 56 Jie, H.B., Schuler, P.J., Lee, S.C., Srivastava, R.M., Argiris, A., Ferrone, S., Whiteside, T.L., Ferris, R.L., CTLA-4(+) regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res 75 (2015), 2200–2210.
57. 57 Kohrt, H.E., Colevas, A.D., Houot, R., Weiskopf, K., Goldstein, M.J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Investig 124 (2014), 2668–2682.
58. 58 Srivastava, R.M., Trivedi, S., Concha-Benavente, F., Gibson, S.P., Reeder, C., Ferrone, S., Ferris, R.L., CD137 stimulation enhances cetuximab-induced natural killer: dendritic cell priming of antitumor T-cell immunity in patients with head and neck cancer. Clin Cancer Res 23 (2017), 707–716.
59. 59 White, R.A., Malkoski, S.P., Wang, X.J., TGFbeta signaling in head and neck squamous cell carcinoma. Oncogene 29 (2010), 5437–5446.